1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsFunds small business R&D in biomedical and health-related AI applications (e. g. , diagnostics, therapeutics, data analysis) through the omnibus solicitation, with potential for AI-focused proposals aligned to NIH institutes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U. S. small businesses meeting SBA eligibility; for-profit; projects must align with NIH mission areas. Confirm the full requirements in the official notice before applying.
The current listing shows phase I up to ~$323,000; Phase II up to ~$2.15M. Verify award ceilings, matching requirements, and allowable costs in the official notice.
NIH Small Business Innovation Research (SBIR) Phase I/II (PHS Omnibus) is funded by National Institutes of Health. Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article